Engineered immune cells take on Hard-to-Treat scleroderma

NCT ID NCT07355972

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment called CT1195E CAR-T cells for people with severe systemic sclerosis (scleroderma) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack the disease. The main goals are to check safety, find the right dose, and see if it can control the disease. Only 12 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SSC-SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SSC-SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Wuhan Union Hospita
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.